No relevant literature was identified regarding the clinical effectiveness or cost-effectiveness of onabotulinum toxin A (Botox) for reducing spasticity in patients with traumatic or non-traumatic–acquired brain injury.
Authors of 1 evidence-based guideline recommend the use of botulinum toxin (subtype and formulation not specified) for the treatment of spasticity associated with traumatic brain injury.